RETA רווח נקי למניה ב-12 החודשים האחרונים Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals (RETA) is implementing eco-friendly chemical synthesis and zero-waste laboratory cycles. The company's annual revenue per unit visualizes this progress, where the -2.99 level captures the latest values. A monopoly status in Friedreich's ataxia therapy precludes dumping, while the inelastic demand for Skyclarys guarantees a steady cash flow, ensuring the high commercial resilience of the patent portfolio.

Net income per share over 12 months measures actual equity income, excluding the impact of volatility in the number of securities. The integration of Reata Pharmaceuticals (RETA) teams into Biogen structures stabilizes operating expenses, directly affecting the calculation base of this metric. This chart of net income per share over 12 months allows for the elimination of accounting distortions. This price action confirms the effectiveness of retaining key competencies, which guarantees capital stability over the long term.